This clinical trial aims at determining the dose and schedule of administration of TG6050 for further development, primarly based on the assessment of the safety and tolerability of single and repeated IV infusions at escalating doses in patients with advanced NSCLC.
This is a phase I, open-label, dose-escalation trial of TG6050 administered by single or repeated IV infusion(s).